

c) treating the allantoic tissue with a compound; and

d) observing the vascularization of the allantoic tissue treated with the compound, wherein an alteration in the vascularization of the allantoic tissue treated with the compound as compared to an allantoic tissue not treated with the compound indicates that the compound affects vascularization of an allantoic tissue.

29. (New Claim) A method of observing vascularization of allantois tissue *in vitro* comprising:

a) isolating allantoic tissue comprising a nucleic acid sequence encoding a marker protein operably linked to a promoter, wherein said allantoic tissue functionally expresses said marker protein to detectable levels,

b) culturing said allantoic tissue *in vitro*, and

c) observing the vascularization of the allantoic tissue.

REMARKS

The September 12, 2001 Office Action has made a double patenting rejection of claims 24 - 27, objected to the specification and claim 27 and rejected all claims under 35 U.S.C. § 112 and § 102(b). In light of the amendments above, the enclosed Declaration and the